Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimzelx in Adult Onset Pityriasis Rubra Pilaris
NCT07497620Phase 4Not yet recruiting
- Sponsor
- Mayo Clinic
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of bimekizumab in pityriasis rubra pilaris (PRP), sponsored by Mayo Clinic. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
bimekizumab
03
Conditions
pityriasis rubra pilaris (PRP)
Beyond the preview
Go deeper on NCT07497620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07497620.